Aralez Pharmaceuticals Inc said the US District Court for the District of New Jersey upheld the validity of two patents owned by a subsidiary of Aralez and licensed to Horizon Pharma plc covering Vimovo (naproxen/esomeprazole magnesium).
Aralez said Dr. Reddy’s Laboratories Inc and Dr. Reddy’s Laboratories Ltd, Mylan Pharmaceuticals Inc, Mylan Laboratories Ltd and Mylan Inc, and Lupin Ltd and Lupin Pharmaceuticals Inc “would infringe at least one of the two patents with their proposed generic naproxen/esomeprazole magnesium products.”
Aralez CEO Adrian Adams said: “We are very pleased that the fair and appropriate ruling regarding this litigation was rendered by the United States District Court for the District of New Jersey.
“This demonstrates the strength of our intellectual property portfolio for Vimovo and Yosprala. We remain committed to aggressively defending our intellectual property.”